261 related articles for article (PubMed ID: 33962861)
1. Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC
Inada M; Ishikane M; Terada M; Matsunaga A; Maeda K; Tsuchiya K; Miura K; Sairenji Y; Kinoshita N; Ujiie M; Kutsuna S; Ishizaka Y; Mitsuya H; Ohmagari N
J Infect Chemother; 2021 Jul; 27(7):1063-1067. PubMed ID: 33962861
[TBL] [Abstract][Full Text] [Related]
2. A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection.
Beppu H; Ogawa T; Ishikane M; Kawanishi T; Fukuda T; Sato L; Matsunaga A; Maeda K; Katagiri D; Ishizaka Y; Mitsuya H; Ohmagari N; Yasui F; Kohara M; Kikuchi K; Wakai S
CEN Case Rep; 2022 Nov; 11(4):422-427. PubMed ID: 35266095
[TBL] [Abstract][Full Text] [Related]
3. Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing.
To KK; Hung IF; Ip JD; Chu AW; Chan WM; Tam AR; Fong CH; Yuan S; Tsoi HW; Ng AC; Lee LL; Wan P; Tso EY; To WK; Tsang DN; Chan KH; Huang JD; Kok KH; Cheng VC; Yuen KY
Clin Infect Dis; 2021 Nov; 73(9):e2946-e2951. PubMed ID: 32840608
[TBL] [Abstract][Full Text] [Related]
4. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
[TBL] [Abstract][Full Text] [Related]
5. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
[TBL] [Abstract][Full Text] [Related]
6. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
Front Immunol; 2021; 12():793953. PubMed ID: 34899762
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.
Trieu MC; Bansal A; Madsen A; Zhou F; Sævik M; Vahokoski J; Brokstad KA; Krammer F; Tøndel C; Mohn KGI; Blomberg B; Langeland N; Cox RJ;
J Infect Dis; 2021 Feb; 223(4):589-599. PubMed ID: 33247924
[TBL] [Abstract][Full Text] [Related]
9. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.
Havervall S; Ng H; Jernbom Falk A; Greilert-Norin N; Månberg A; Marking U; Laurén I; Gabrielsson L; Salomonsson AC; Aguilera K; Kihlgren M; Månsson M; Rosell A; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Lord M; Åberg M; Hedhammar M; Tegel H; Dönnes P; Phillipson M; Nilsson P; Klingström J; Mangsbo S; Hober S; Thålin C
J Intern Med; 2022 Jan; 291(1):72-80. PubMed ID: 34459525
[TBL] [Abstract][Full Text] [Related]
10. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients.
Chansaenroj J; Yorsaeng R; Puenpa J; Wanlapakorn N; Chirathaworn C; Sudhinaraset N; Sripramote M; Chalongviriyalert P; Jirajariyavej S; Kiatpanabhikul P; Saiyarin J; Soudon C; Thienfaidee O; Ayuthaya TPN; Brukesawan C; Intharasongkroh D; Chaiwanichsiri D; Issarasongkhram M; Kitphati R; Mungaomklang A; Thitithanyanont A; Nagavajara P; Poovorawan Y
PLoS One; 2022; 17(4):e0267102. PubMed ID: 35446889
[TBL] [Abstract][Full Text] [Related]
11. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].
Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M
Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235
[TBL] [Abstract][Full Text] [Related]
12. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
13. Viral Shedding among Re-Positive Severe Acute Respiratory Syndrome Coronavirus-2 Positive Individuals in Republic of Korea.
Kim JM; Ryu B; Choe YJ; Jo HJ; Lee H; Kim HM; Lee NJ; Rhee JE; Chung YS; Han MG; Kim EJ; Park Y; Gwack J; Jin Y; Song J; Seo S; Gill B; Kim H; Park Y; Yoo CK; Jeong EK
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696519
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
Front Immunol; 2022; 13():829665. PubMed ID: 35154152
[TBL] [Abstract][Full Text] [Related]
15. Low Innate Immunity and Lagged Adaptive Immune Response in the Re-Tested Viral RNA Positivity of a COVID-19 Patient.
Lai C; Liu X; Yan Q; Lv H; Zhou L; Hu L; Cai Y; Wang G; Chen Y; Chai R; Liu Z; Xu Y; Huang W; Xiao F; Hu L; Li Y; Huang J; Zhou Q; Li L; Peng T; Zhang H; Zhang Z; Chen L; Chen C; Ji T
Front Immunol; 2021; 12():664619. PubMed ID: 34305895
[TBL] [Abstract][Full Text] [Related]
16. A case report of breakthrough infection with the SARS-CoV-2 delta variant and household transmission: Role of vaccination, anti-spike IgG and neutralizing activity.
Moriyama Y; Ishikane M; Ueno M; Matsunaga A; Ishizaka Y; Arashiro T; Kanno T; Suzuki T; Kimura K
J Infect Chemother; 2022 Jul; 28(7):962-964. PubMed ID: 35461768
[TBL] [Abstract][Full Text] [Related]
17. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
McAndrews KM; Dowlatshahi DP; Dai J; Becker LM; Hensel J; Snowden LM; Leveille JM; Brunner MR; Holden KW; Hopkins NS; Harris AM; Kumpati J; Whitt MA; Lee JJ; Ostrosky-Zeichner LL; Papanna R; LeBleu VS; Allison JP; Kalluri R
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32796155
[TBL] [Abstract][Full Text] [Related]
19. A Third Dose of an Inactivated Vaccine Dramatically Increased the Levels and Decay Times of Anti-SARS-CoV-2 Antibodies, but Disappointingly Declined Again: A Prospective, Longitudinal, Cohort Study at 18 Serial Time Points Over 368 Days.
Liang XM; Xu QY; Jia ZJ; Wu MJ; Liu YY; Lin LR; Liu LL; Yang TC
Front Immunol; 2022; 13():876037. PubMed ID: 35572536
[TBL] [Abstract][Full Text] [Related]
20. Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays.
Tang MS; Case JB; Franks CE; Chen RE; Anderson NW; Henderson JP; Diamond MS; Gronowski AM; Farnsworth CW
Clin Chem; 2020 Dec; 66(12):1538-1547. PubMed ID: 32894750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
